Why Bill Ackman and Valeant Are Bidding for Allergan

So far this seems like a great opportunity for everyone involved. But this is only the beginning.

The Motley Fool
You’re reading a free article with opinions that may differ from The Motley Fool’s premium investing services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn more

The management team, board members, and shareholders of multi-specialty healthcare company Allergan (NYSE:AGN) certainly have a lot to think about. Canada-based Valeant Pharmaceuticals (TSX: VRX)(NYSE: VRX) has teamed up with hedge fund Pershing Square (led by activist investor Bill Ackman) to bid for the company.

The total value of the bid is $47 billion, approximately $153 per share, with 30% of that being paid in cash, and the rest in stock. The offering price is a 30% premium to Allergan’s closing price back on April 10, when Pershing Square ratcheted up its purchases of Allergan stock. Yet the market still expects the offer to be sweetened; the shares currently trade in the mid-$160s (all figures in USD).

Valeant and Pershing have been prepping for this day for months. Valeant has already lined up funding from RBC and Barclays. Meanwhile, Pershing has accumulated a 9.7% stake in Allergan. Pershing is also committed to being a long-term shareholder in Valeant should the transaction close.

The numbers are compelling

Mr. Ackman and Valeant see lots of opportunity to add value by buying Allergan. They have estimated that a combined company would generate at least $2.7 billion in annual cost synergies, with “significant” revenue synergies as well. The transaction also allows Valeant to apply its low tax rate to Allergan’s earnings. Altogether Mr. Ackman and Pershing expect earnings accretion of 25-30%.

From there, the company should expect to see organic revenue growth in the high single digits, with cash EPS growing by 15-20% per year.

How will this be done?

Of the $2.7 billion in cost synergies, two-thirds will come from general corporate expenses. For example, the corporate and regional headquarters will be rationalized. Other redundant functions will be eliminated.

The other third will come from reduced R&D spending. Valeant is well-known for this, as the company prefers to acquire products rather than develop them in-house. Meanwhile, Allergan has a mixed track record when it comes to R&D, to put it mildly. As pointed out by Mr. Ackman and Valeant, Allergan has spent $9.5 billion on R&D since 1998 – yet ~80% of the company’s 2013 revenue came from acquired products.

Mr. Ackman and Valeant pointed out other deficiencies in Allergan’s operating model, promising to wring cost savings simply by applying Valeant’s strategy to Allergan’s business. Mr. Ackman stated that he believes no other company can rationally make a higher bid for Allergan’s shares than he and Valeant just did.

So what happens next?

This is really just the beginning of the process. The acquirers still need to discuss the transaction with Allergan, as well as pitch the deal to the company’s shareholders. And Valeant’s shareholders will get a chance to voice their opinion too. But the latter group already seems on board; Valeant’s shares have risen by nearly 8% in response to the news.

Foolish bottom line

So far, this appears to be a match made in heaven. But we have not heard Allergan’s side of the story yet, and if the company’s board opposes this transaction, things could get ugly very quickly. Stay tuned for more developments.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Benjamin Sinclair holds no positions in any of the stocks mentioned in this article. The Motley Fool owns shares of Valeant Pharmaceuticals.

More on Investing

Hands holding trophy cup on sky background
Investing

3 Growth Stocks That Could Be Huge Winners in the Next Decade and Beyond

Here are three top TSX growth stocks that may be worth a look, given the significant valuation declines these stocks…

Read more »

edit Back view of hugging couple standing with real estate agent in front of house for sale
Dividend Stocks

Why Real Estate Stocks Are a No-Brainer Addition to Your Portfolio

Real estate stocks, especially REITs, offer some distinct advantages over other types of stocks, making them must-have additions to most…

Read more »

Man data analyze
Stocks for Beginners

Beginners: 2 Market-Beating Stocks Just Getting Started

Brookfield Asset Management (TSX:BAM.A)(NYSE:BAM) and Constellation Software (TSX:CSU) are proven market beaters that could continue their ways.

Read more »

oil and natural gas
Energy Stocks

Small OPEC+ Oil-Output Hike: Buy More Energy Stocks?

Energy stocks could soar higher, because oil markets will remain tight due to the small production increase by OPEC+.

Read more »

Various Canadian dollars in gray pants pocket
Dividend Stocks

3 Top TSX Dividend Stocks to Buy for Monthly Passive Income

Top TSX stocks with monthly dividends now trade at cheap prices for investors seeking passive income.

Read more »

edit Person using calculator next to charts and graphs
Investing

Where to Invest $500 in the TSX Right Now

Long-term investors can look to buy stocks, including Suncor Energy and Shopify, as they are poised to outpace the broader…

Read more »

Canadian Dollars
Dividend Stocks

Create Free Passive Income and Turn it Into Thousands With 1 TSX Stock

If you can't afford to invest, you can certainly create passive income another way and use that to invest in…

Read more »

falling red arrow and lifting
Investing

2 Oversold TSX Stocks That Should Bounce Back

Stocks that are oversold without an external catalyst like a market crash or a weak sector might be risky buys,…

Read more »